Shenzhen Salubris Pharmaceuticals (Xinlitai) has announced a significant milestone in its global oncology strategy through its U.S.-based subsidiary, Salubris Biotherapeutics. At the 2026 American Association for Cancer Research (AACR) Annual Meeting, the company presented Phase 1/2 expansion cohort data for JK06, a dual-epitope antibody-drug conjugate (ADC) targeting the 5T4 protein. The findings indicate that the drug maintains a robust safety profile and demonstrates clinical efficacy in patients with unresectable, locally advanced, or metastatic solid tumors, including non-small cell lung cancer (NSCLC) and breast cancer.
The development of JK06 represents a sophisticated evolution in ADC technology, utilizing a dual-epitope design that achieves picomolar-level affinity for the 5T4 antigen. This high-precision binding triggers rapid, target-mediated endocytosis, allowing the drug's payload—the potent cytotoxic agent MMAE—to be delivered directly into the cancer cells. By using site-specific conjugation technology, Salubris aims to overcome the stability and toxicity issues that have historically plagued earlier generations of antibody-based therapies.
Currently, JK06 is undergoing an open-label, dose-escalation, and expansion study across clinical sites in Europe. The research is designed to map the safety, pharmacokinetics, and preliminary efficacy of the drug in patients who express the 5T4 protein, a common marker in various aggressive solid tumors. With the expansion phase now underway, the company has signaled its intention to move toward monotherapy cohorts and eventual combination trials with other standard-of-care treatments.
This progress underscores a broader trend of Chinese pharmaceutical firms shifting from domestic generic manufacturing to high-stakes global innovation. By conducting simultaneous trials in the United States and Europe, Salubris is positioning itself to compete in the high-growth ADC market, which has seen multi-billion dollar licensing deals in recent years. For global investors and healthcare providers, the emergence of JK06 highlights the increasing technical maturity of Chinese biotech subsidiaries operating in Western regulatory environments.